变应原免疫治疗疗效相关生物标志物研究进展  

Progress of biomarkers for the efficacy of allergen immunotherapy

作　　者：陈希亚 何静 陈志敏[1] Chen Xiya;He Jing;Chen Zhimin(Department of Pulmonology,Children's Hospital,Zhejiang University School of Medicine,National Clinical Research Center for Child Health,Hangzhou 310052,China)

机构地区：[1]浙江大学医学院附属儿童医院呼吸科、国家儿童健康与疾病临床医学研究中心,杭州310052

出　　处：《国际儿科学杂志》2024年第3期143-147,共5页International Journal of Pediatrics

基　　金：国家自然科学基金面上项目(81870023)。

摘　　要：变应原免疫治疗(allergen immunotherapy,AIT)是目前呼吸道过敏性疾病的对因治疗,可以改变疾病的自然进程。但由于患者自身免疫状态、过敏触发因素的复杂性及其与AIT疫苗之间复杂的关系,仍有约40%的变应性鼻炎和10%~20%的哮喘患者对AIT治疗没有最佳反应,甚至AIT治疗无效。因此,寻找可以评价和预测AIT疗效的生物标志物进而优化AIT治疗策略一直是过敏领域的重点与难点。目前研究发现体外多种血清学指标可能与AIT疗效相关,但其作为可预测疗效的生物标志物的价值仍有待进一步验证。该文就AIT疗效相关血清学候选生物标志物的研究现状作一综述。Allergen immunotherapy(AIT)is currently the etiological treatment for respiratory allergic diseases,which can change the natural course of the disease.However,due to the complexity of patients'autoimmune status,allergy triggers and their complicated relationship with AIT vaccines,there are still about 40%of allergic rhinitis and 10%-20%of asthma patients who respond nonoptimally or even don't show any response to AIT.Thus,searching biomarkers that can evaluate and predict the efficacy of AIT and optimize the AIT strategy has been a major focus and challenge in allergy field.Currently,several serologic biomarkers have been found to be associated with AIT efficacy in vitro,but their value as predictive biomarkers of AIT efficacy needs to be further verified.This article reviews the research progress of serologic candidate biomarkers for AIT efficacy.

关 键 词：变应原免疫治疗 变应性鼻炎 哮喘 生物标志物 

分 类 号：R56[医药卫生—呼吸系统]